Corneal intraepithelial neoplasia as a cause of visual acuity decrease: a low-cost approach
Alejandro Villarreal-González 1, Carlos Alberto Romo-Arpio 2, Pablo Villarreal-Guerra 3, Alejandro Sámano-Guerrero 4
1 Cirujano Oftalmólogo, Subespecialista en Córnea y Superficie Ocular, Jefe del Departamento de Córnea y Superficie Ocular, Centro Oftalmológico del Valle, San Pedro Garza García, N.L., México; 2 Cirujano Oftalmólogo, Subespecialista en Glaucoma y Segmento Anterior, Jefe del Departamento de Glaucoma, Centro Oftalmológico del Valle, San Pedro Garza García, N.L., México; 3 Cirujano Oftalmólogo, Maestría en Bioética y Educación Superior, Doctorando en Bioética, Profesor de Bioética y Oftalmología General, Universidad de Monterrey, San Pedro Garza García, N.L., México; 4 Médico Cirujano y Partero, Investigador Clínico, Director de Consultora en Investigación Biomédica Analimed, San Pedro Garza García, N.L., México
Alejandro Villarreal-González, Carlos Alberto Romo-Arpio, Pablo Villarreal-Guerra, Alejandro Sámano-Guerrero
La información completa de afiliaciones y autor de correspondencia está disponible en la versión original en PDF.
*Correspondencia: Alejandro Sámano-Guerrero, Email no disponible
Resumen
Introduction: Corneal intraepithelial neoplasia is a dysplastic condition within the ocular surface squamous cell neoplasia spectrum. It is a rare condition that is seldom suspected, especially at its diffuse presentation. Once suspected, diagnosis and treatment are easy for a condition that if left untreated could be devastating. Clinical case: We present the case of a 63-year-old male patient presenting with a history of two weeks of right eye visual acuity decrease as only symptom. Right eye visual acuity was 20/40 and physical examination revealed a right cornea upper half geographic lesion with frosted appearance. After diagnostic rule out, epithelial scraping was decided, with low-grade corneal intraepithelial neoplasia reported by the pathology department. Management with mitomycin C 0.02% in two 2-week cycles with 3 topical applications per day, accompanied by fluorometholone 0.1% at the same dosage was then decided. Conclusions: The authors recommend the use of mitomycin C in developing countries.
